GT Biopharma, Inc.
Price Action
Technical Summary
WEAKENINGGT Biopharma, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 43), showing significant lag compared to the market leaders. Earnings growth of 67% provides fundamental context to the price action. Investors should exercise caution due to high volatility (126% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.45 | -4.83% | BELOW |
| 50 SMA | $0.40 | +6.67% | ABOVE |
| 100 SMA | $0.43 | +1.08% | ABOVE |
| 150 SMA | $0.52 | -18.00% | BELOW |
| 200 SMA | $0.57 | -24.83% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is GTBP in an uptrend right now?
GTBP has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is GTBP overbought or oversold?
GTBP's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is GTBP outperforming the market?
GTBP has a Relative Strength (RS) Rating of 43 out of 99. GTBP is currently lagging the broader market.
Where is GTBP in its 52-week range?
GTBP is trading at $0.43, which is 12% of its 52-week high ($3.73) and 5% above its 52-week low ($0.27).
How volatile is GTBP?
GTBP has a Beta of 1.84 and 52-week volatility of 126%. It's more volatile than the S&P 500 - expect bigger swings.